"The risk of depression following a diagnosis of diabetes falls during the second decade of having the disease and then rapidly rises, Australian researchers have discovered, in a study that suggests there is a J-shaped relationship between the tw"...
NARDIL (phenelzine) is a potent inhibitor of monoamine oxidase. Because this enzyme is widely distributed throughout the body, diverse pharmacologic effects can be expected to occur. When they occur, such effects tend to be mild or moderate in severity (see below), often subside as treatment continues, and can be minimized by adjusting dosage; rarely is it necessary to institute counteracting measures or to discontinue NARDIL (phenelzine) .
Common side effects include:
Nervous System — Dizziness, headache, drowsiness, sleep disturbances (including insomnia and hypersomnia), fatigue, weakness, tremors, twitching, myoclonic movements, hyperreflexia.
Gastrointestinal — Constipation, dry mouth, gastrointestinal disturbances, elevated serum transaminases (without accompanying signs and symptoms).
Metabolic — Weight gain.
Less common mild to moderate side effects (some of which have been reported in a single patient or by a single physician) include:
Genitourinary — Urinary retention.
Metabolic — Hypernatremia.
Dermatologic — Pruritus, skin rash, sweating.
Although reported less frequently, and sometimes only once, additional severe side effects include:
Nervous System — Ataxia, shock-like coma, toxic delirium, manic reaction, convulsions, acute anxiety reaction, precipitation of schizophrenia, transient respiratory and cardiovascular depression following ECT.
Gastrointestinal —To date, fatal progressive necrotizing hepatocellular damage has been reported in very few patients. Reversible jaundice.
Hematologic — Leukopenia.
Immunologic — Lupus-like syndrome
Metabolic — Hypermetabolic syndrome (which may include, but is not limited to, hyperpyrexia, tachycardia, tachypnea, muscular rigidity, elevated CK levels, metabolic acidosis, hypoxia, coma and may resemble an overdose).
Respiratory — Edema of the glottis.
General — Fever associated with increased muscle tone.
Withdrawal may be associated with nausea, vomiting, and malaise.
An uncommon withdrawal syndrome following abrupt withdrawal of NARDIL (phenelzine) has been infrequently reported. Signs and symptoms of this syndrome generally commence 24 to 72 hours after drug discontinuation and may range from vivid nightmares with agitation to frank psychosis and convulsions. This syndrome generally responds to reinstitution of low-dose NARDIL (phenelzine) therapy followed by cautious downward titration and discontinuation.
Read the Nardil (phenelzine) Side Effects Center for a complete guide to possible side effects
In patients receiving nonselective monoamine oxidase (MAO) inhibitors in combination with serotoninergic agents (e.g., dexfenfluramine, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, venlafaxine) there have been reports of serious, sometimes fatal, reactions. Because NARDIL (phenelzine) is a monoamine oxidase (MAO) inhibitor, NARDIL (phenelzine) should not be used concomitantly with a serotoninergic agent (See CONTRAINDICATIONS).
Administration of guanethidine to patients receiving an MAO inhibitor can produce moderate to severe hypertension due to release of catecholamines. At least two weeks should elapse between withdrawal of the MAO inhibitor and the initiation of guanethidine. (see CONTRAINDICATIONS)
Read the Nardil Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 8/29/2007
Additional Nardil Information
Nardil - User Reviews
Nardil User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.